You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameThiothixene
Accession NumberDB01623
TypeSmall Molecule
GroupsApproved
DescriptionA thioxanthine used as an antipsychotic agent. Its effects are similar to the phenothiazine antipsychotics. [PubChem]
Structure
Thumb
Synonyms
(e)-thiothixene
cis-thiothixene
Thiothixine
Tiotixene
Tiotixeno
Tiotixenum
External Identifiers
  • NSC-108165
  • P-4657 B
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Navane Cap 2mgcapsule2 mgoralErfa Canada 2012 Inc1969-12-312015-06-05Canada
Navane Cap 5mgcapsule5 mgoralErfa Canada 2012 Inc1969-12-31Not applicableCanada
Navane Capsules 10mgcapsule10 mgoralErfa Canada 2012 Inc1969-12-312015-06-05Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Thiothixenecapsule10 mg/1oralSandoz Inc1987-06-24Not applicableUs
Thiothixenecapsule1 mg/1oralMylan Pharmaceuticals Inc.1987-06-23Not applicableUs
Thiothixenecapsule2 mg/1oralMylan Institutional Inc.1998-03-09Not applicableUs
Thiothixenecapsule2 mg/1oralREMEDYREPACK INC.2011-08-17Not applicableUs
Thiothixenecapsule5 mg/1oralCarilion Materials Management1987-06-23Not applicableUs
Thiothixenecapsule1 mg/1oralSandoz Inc1987-06-24Not applicableUs
Thiothixenecapsule5 mg/1oralRebel Distributors Corp1987-06-24Not applicableUs
Thiothixenecapsule2 mg/1oralMylan Pharmaceuticals Inc.1987-06-23Not applicableUs
Thiothixenecapsule5 mg/1oralMylan Institutional Inc.1998-03-05Not applicableUs
Thiothixenecapsule1 mg/1oralREMEDYREPACK INC.2011-10-25Not applicableUs
Thiothixenecapsule2 mg/1oralSandoz Inc1987-06-24Not applicableUs
Thiothixenecapsule10 mg/1oralREMEDYREPACK INC.2011-07-19Not applicableUs
Thiothixenecapsule5 mg/1oralMylan Pharmaceuticals Inc.1987-06-23Not applicableUs
Thiothixenecapsule10 mg/1oralMylan Institutional Inc.1998-07-24Not applicableUs
Thiothixenecapsule2 mg/1oralREMEDYREPACK INC.2011-12-07Not applicableUs
Thiothixenecapsule5 mg/1oralSandoz Inc1987-06-24Not applicableUs
Thiothixenecapsule5 mg/1oralREMEDYREPACK INC.2011-07-22Not applicableUs
Thiothixenecapsule10 mg/1oralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
Thiothixenecapsule10 mg/1oralMylan Pharmaceuticals Inc.1987-06-23Not applicableUs
Thiothixenecapsule5 mg/1oralREMEDYREPACK INC.2011-11-14Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
NavanNot Available
NavaronNot Available
OrbinamonNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Thiothixene hydrochloride
ThumbNot applicableDBSALT001423
Categories
UNII7318FJ13YJ
CAS number3313-26-6
WeightAverage: 443.625
Monoisotopic: 443.170118567
Chemical FormulaC23H29N3O2S2
InChI KeyInChIKey=GFBKORZTTCHDGY-UWVJOHFNSA-N
InChI
InChI=1S/C23H29N3O2S2/c1-24(2)30(27,28)18-10-11-23-21(17-18)19(20-7-4-5-9-22(20)29-23)8-6-12-26-15-13-25(3)14-16-26/h4-5,7-11,17H,6,12-16H2,1-3H3/b19-8-
IUPAC Name
(9Z)-N,N-dimethyl-9-[3-(4-methylpiperazin-1-yl)propylidene]-9H-thioxanthene-2-sulfonamide
SMILES
CN(C)S(=O)(=O)C1=CC2=C(SC3=CC=CC=C3\C2=C\CCN2CCN(C)CC2)C=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as thioxanthenes. These are organic polycyclic compounds containing a thioxanthene moiety, which is an aromatic tricycle derived from xanthene by replacing the oxygen atom with a sulfur atom.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzothiopyrans
Sub Class1-benzothiopyrans
Direct ParentThioxanthenes
Alternative Parents
Substituents
  • Thioxanthene
  • Diarylthioether
  • Benzenesulfonamide
  • N-alkylpiperazine
  • N-methylpiperazine
  • Benzenoid
  • Piperazine
  • 1,4-diazinane
  • Aminosulfonyl compound
  • Sulfonyl
  • Sulfonic acid derivative
  • Sulfonamide
  • Tertiary aliphatic amine
  • Tertiary amine
  • Azacycle
  • Thioether
  • Hydrocarbon derivative
  • Organosulfur compound
  • Organonitrogen compound
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the management of schizophrenia.
PharmacodynamicsThiothixene is an antipsychotic of the thioxanthene series. Navane possesses certain chemical and pharmacological similarities to the piperazine phenothiazines and differences from the aliphatic group of phenothiazines. Although widely used in the treatment of schizophrenia for several decades, thiothixene is seldom used today in favor of atypical antipsychotics such as risperidone.
Mechanism of actionThiothixene acts as an antagonist (blocking agent) on different postsysnaptic receptors -on dopaminergic-receptors (subtypes D1, D2, D3 and D4 - different antipsychotic properties on productive and unproductive symptoms), on serotonergic-receptors (5-HT1 and 5-HT2, with anxiolytic, antidepressive and antiaggressive properties as well as an attenuation of extrapypramidal side-effects, but also leading to weight gain, fall in blood pressure, sedation and ejaculation difficulties), on histaminergic-receptors (H1-receptors, sedation, antiemesis, vertigo, fall in blood pressure and weight gain), alpha1/alpha2-receptors (antisympathomimetic properties, lowering of blood pressure, reflex tachycardia, vertigo, sedation, hypersalivation and incontinence as well as sexual dysfunction, but may also attenuate pseudoparkinsonism - controversial) and finally on muscarinic (cholinergic) M1/M2-receptors (causing anticholinergic symptoms like dry mouth, blurred vision, obstipation, difficulty/inability to urinate, sinus tachycardia, ECG-changes and loss of memory, but the anticholinergic action may attenuate extrapyramidal side-effects).
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Hepatic.

Route of eliminationNot Available
Half life10-20 hours
ClearanceNot Available
ToxicitySymptoms of overdose include central nervous system depression, coma, difficulty swallowing, dizziness, drowsiness, head tilted to the side, low blood pressure, muscle twitching, rigid muscles, salivation, tremors, walking disturbances, and weakness.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9969
Blood Brain Barrier+0.9437
Caco-2 permeable-0.6277
P-glycoprotein substrateSubstrate0.8707
P-glycoprotein inhibitor IInhibitor0.9247
P-glycoprotein inhibitor IIInhibitor0.9036
Renal organic cation transporterNon-inhibitor0.5373
CYP450 2C9 substrateNon-substrate0.7951
CYP450 2D6 substrateNon-substrate0.9117
CYP450 3A4 substrateSubstrate0.5269
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorInhibitor0.8933
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorInhibitor0.796
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5406
Ames testNon AMES toxic0.651
CarcinogenicityNon-carcinogens0.8173
BiodegradationNot ready biodegradable0.947
Rat acute toxicity2.7586 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.5093
hERG inhibition (predictor II)Non-inhibitor0.7259
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Capsuleoral2 mg
Capsuleoral5 mg
Capsuleoral10 mg
Capsuleoral1 mg/1
Capsuleoral10 mg/1
Capsuleoral2 mg/1
Capsuleoral5 mg/1
Prices
Unit descriptionCostUnit
Navane 20 mg capsule3.15USD capsule
Navane 10 mg capsule1.66USD capsule
Navane 5 mg capsule1.2USD capsule
Navane 2 mg capsule0.8USD capsule
Thiothixene 10 mg capsule0.67USD capsule
Thiothixene 5 mg capsule0.47USD capsule
Thiothixene 2 mg capsule0.31USD capsule
Thiothixene 1 mg capsule0.24USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.0139 mg/mLALOGPS
logP4.01ALOGPS
logP3.36ChemAxon
logS-4.5ALOGPS
pKa (Strongest Basic)8.56ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area43.86 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity137.85 m3·mol-1ChemAxon
Polarizability50.35 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesN05AF04
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
3,4-MethylenedioxyamphetamineThiothixene may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.
3,4-MethylenedioxymethamphetamineThiothixene may decrease the stimulatory activities of 3,4-Methylenedioxymethamphetamine.
7-NitroindazoleThe risk or severity of adverse effects can be increased when Thiothixene is combined with 7-Nitroindazole.
AbirateroneThe serum concentration of Thiothixene can be increased when it is combined with Abiraterone.
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Thiothixene.
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Thiothixene.
adipiplonThe risk or severity of adverse effects can be increased when Thiothixene is combined with adipiplon.
AgomelatineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Agomelatine.
AlfaxaloneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Alfaxalone.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Thiothixene.
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Thiothixene.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Thiothixene.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Thiothixene.
AmiodaroneThiothixene may increase the QTc-prolonging activities of Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Thiothixene is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Thiothixene.
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Thiothixene.
AmoxapineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Thiothixene is combined with Amperozide.
AmphetamineThiothixene may decrease the stimulatory activities of Amphetamine.
AnagrelideThiothixene may increase the QTc-prolonging activities of Anagrelide.
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Thiothixene.
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Thiothixene.
Arsenic trioxideThiothixene may increase the QTc-prolonging activities of Arsenic trioxide.
ArtemetherThiothixene may increase the QTc-prolonging activities of Artemether.
ArticaineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Articaine.
AsenapineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Asenapine.
AzaperoneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Azaperone.
AzelastineThiothixene may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Thiothixene.
AzithromycinThiothixene may increase the QTc-prolonging activities of Azithromycin.
AzithromycinThe metabolism of Thiothixene can be decreased when combined with Azithromycin.
BaclofenThe risk or severity of adverse effects can be increased when Thiothixene is combined with Baclofen.
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Thiothixene.
BedaquilineThiothixene may increase the QTc-prolonging activities of Bedaquiline.
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Thiothixene.
BenzphetamineThiothixene may decrease the stimulatory activities of Benzphetamine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Thiothixene is combined with Benzyl alcohol.
BortezomibThe metabolism of Thiothixene can be decreased when combined with Bortezomib.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Thiothixene is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Thiothixene.
BrimonidineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Thiothixene.
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Thiothixene.
BrompheniramineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Thiothixene is combined with Brotizolam.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Thiothixene.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Thiothixene.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Thiothixene.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Thiothixene.
ButacaineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Thiothixene is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Thiothixene is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Thiothixene.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Thiothixene.
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Thiothixene.
CaffeineThe metabolism of Thiothixene can be decreased when combined with Caffeine.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Thiothixene.
CarbinoxamineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Thiothixene.
CarisoprodolThe risk or severity of adverse effects can be increased when Thiothixene is combined with Carisoprodol.
CeritinibThiothixene may increase the QTc-prolonging activities of Ceritinib.
CetirizineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Cetirizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Thiothixene.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Thiothixene.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Thiothixene.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Thiothixene.
ChloroquineThiothixene may increase the QTc-prolonging activities of Chloroquine.
ChlorphenamineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Chlorphenamine.
ChlorphentermineThiothixene may decrease the stimulatory activities of Chlorphentermine.
ChlorpromazineThiothixene may increase the QTc-prolonging activities of Chlorpromazine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Thiothixene.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Thiothixene.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Chlorzoxazone.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Thiothixene.
CiprofloxacinThiothixene may increase the QTc-prolonging activities of Ciprofloxacin.
CisaprideThiothixene may increase the QTc-prolonging activities of Cisapride.
CitalopramThe risk or severity of adverse effects can be increased when Thiothixene is combined with Citalopram.
ClarithromycinThiothixene may increase the QTc-prolonging activities of Clarithromycin.
ClemastineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Thiothixene is combined with Clidinium.
ClobazamThe risk or severity of adverse effects can be increased when Thiothixene is combined with Clobazam.
clomethiazoleThe risk or severity of adverse effects can be increased when Thiothixene is combined with clomethiazole.
ClomipramineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Thiothixene is combined with Clonazepam.
ClonidineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Clonidine.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Thiothixene.
ClotrimazoleThe metabolism of Thiothixene can be decreased when combined with Clotrimazole.
ClozapineThiothixene may increase the QTc-prolonging activities of Clozapine.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Thiothixene.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Thiothixene.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Thiothixene.
CrizotinibThiothixene may increase the QTc-prolonging activities of Crizotinib.
CyclizineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Thiothixene.
CyproheptadineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Cyproheptadine.
Cyproterone acetateThe serum concentration of Thiothixene can be decreased when it is combined with Cyproterone acetate.
DantroleneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Dantrolene.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Thiothixene.
DapoxetineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Dapoxetine.
DeferasiroxThe serum concentration of Thiothixene can be increased when it is combined with Deferasirox.
deramciclaneThe risk or severity of adverse effects can be increased when Thiothixene is combined with deramciclane.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Thiothixene.
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Thiothixene.
DesloratadineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Desloratadine.
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Thiothixene.
DetomidineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Detomidine.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Dexbrompheniramine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Thiothixene.
DextroamphetamineThiothixene may decrease the stimulatory activities of Dextroamphetamine.
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Thiothixene.
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Thiothixene.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Thiothixene.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Thiothixene.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Thiothixene.
DifenoxinThe risk or severity of adverse effects can be increased when Thiothixene is combined with Difenoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Thiothixene.
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Thiothixene.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Thiothixene.
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Thiothixene.
DimenhydrinateThe risk or severity of adverse effects can be increased when Thiothixene is combined with Dimenhydrinate.
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Thiothixene.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Thiothixene.
DisopyramideThiothixene may increase the QTc-prolonging activities of Disopyramide.
DofetilideThiothixene may increase the QTc-prolonging activities of Dofetilide.
DolasetronThiothixene may increase the QTc-prolonging activities of Dolasetron.
DomperidoneThiothixene may increase the QTc-prolonging activities of Domperidone.
DoramectinThe risk or severity of adverse effects can be increased when Thiothixene is combined with Doramectin.
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Thiothixene.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Thiothixene.
DoxylamineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when Thiothixene is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Thiothixene.
DronedaroneThiothixene may increase the QTc-prolonging activities of Dronedarone.
DroperidolThiothixene may increase the QTc-prolonging activities of Droperidol.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Thiothixene.
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Thiothixene.
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Thiothixene.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Thiothixene.
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Thiothixene.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Thiothixene is combined with ECGONINE METHYL ESTER.
EfavirenzThe risk or severity of adverse effects can be increased when Thiothixene is combined with Efavirenz.
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Thiothixene.
EliglustatThiothixene may increase the QTc-prolonging activities of Eliglustat.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Thiothixene.
EntacaponeThe risk or severity of adverse effects can be increased when Thiothixene is combined with Entacapone.
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Thiothixene.
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Thiothixene.
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Thiothixene.
ErythromycinThiothixene may increase the QTc-prolonging activities of Erythromycin.
EscitalopramThe risk or severity of adverse effects can be increased when Thiothixene is combined with Escitalopram.
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Thiothixene.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Thiothixene.
EthanolThiothixene may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Thiothixene.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Thiothixene.
EthosuximideThe risk or severity of adverse effects can be increased when Thiothixene is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Thiothixene is combined with Ethotoin.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Thiothixene is combined with Ethyl carbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Thiothixene.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Thiothixene.
EtidocaineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Thiothixene is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Thiothixene.
EtoperidoneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Etoperidone.
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Thiothixene.
EzogabineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Thiothixene is combined with Felbamate.
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Thiothixene.
FenfluramineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Thiothixene.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Thiothixene.
FexofenadineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Fexofenadine.
FlecainideThiothixene may increase the QTc-prolonging activities of Flecainide.
FlibanserinThe risk or severity of adverse effects can be increased when Thiothixene is combined with Flibanserin.
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Thiothixene.
FlunarizineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Thiothixene.
FluoxetineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Thiothixene.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Thiothixene.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Thiothixene.
FluspirileneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Fluspirilene.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Thiothixene is combined with Fluticasone Propionate.
FluvoxamineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Fluvoxamine.
FosphenytoinThe risk or severity of adverse effects can be increased when Thiothixene is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Thiothixene is combined with Fospropofol.
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Thiothixene.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Thiothixene.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Thiothixene is combined with gabapentin enacarbil.
Gadobenic acidThiothixene may increase the QTc-prolonging activities of Gadobenic acid.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Thiothixene.
GemifloxacinThiothixene may increase the QTc-prolonging activities of Gemifloxacin.
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Thiothixene.
GoserelinThiothixene may increase the QTc-prolonging activities of Goserelin.
GranisetronThiothixene may increase the QTc-prolonging activities of Granisetron.
GuanfacineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Thiothixene.
HaloperidolThiothixene may increase the QTc-prolonging activities of Haloperidol.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Thiothixene.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Thiothixene.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Thiothixene.
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Thiothixene.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Thiothixene.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Thiothixene.
Hydroxyamphetamine hydrobromideThiothixene may decrease the stimulatory activities of Hydroxyamphetamine hydrobromide.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Thiothixene.
HydroxyzineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Hydroxyzine.
IbutilideThiothixene may increase the QTc-prolonging activities of Ibutilide.
IloperidoneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Iloperidone.
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Thiothixene.
IndalpineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Indalpine.
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Thiothixene.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Thiothixene.
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Thiothixene.
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Thiothixene.
KetobemidoneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Ketobemidone.
LamotrigineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Lamotrigine.
LenvatinibThiothixene may increase the QTc-prolonging activities of Lenvatinib.
LeuprolideThiothixene may increase the QTc-prolonging activities of Leuprolide.
LevetiracetamThe risk or severity of adverse effects can be increased when Thiothixene is combined with Levetiracetam.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Thiothixene.
LevocabastineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Thiothixene is combined with Levodopa.
LevofloxacinThiothixene may increase the QTc-prolonging activities of Levofloxacin.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Thiothixene.
LevomilnacipranThe risk or severity of adverse effects can be increased when Thiothixene is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Thiothixene.
LidocaineThe metabolism of Thiothixene can be decreased when combined with Lidocaine.
LidocaineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Lidocaine.
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Thiothixene.
LisdexamfetamineThiothixene may decrease the stimulatory activities of Lisdexamfetamine.
LithiumLithium may increase the neurotoxic activities of Thiothixene.
LithiumThe risk or severity of adverse effects can be increased when Thiothixene is combined with Lithium.
LofentanilThe risk or severity of adverse effects can be increased when Thiothixene is combined with Lofentanil.
LopinavirThiothixene may increase the QTc-prolonging activities of Lopinavir.
LoratadineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Thiothixene.
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Thiothixene.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Thiothixene.
Lu AA21004The risk or severity of adverse effects can be increased when Thiothixene is combined with Lu AA21004.
LumefantrineThiothixene may increase the QTc-prolonging activities of Lumefantrine.
LurasidoneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Thiothixene.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Thiothixene is combined with Magnesium Sulfate.
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Thiothixene.
MeclizineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Medetomidine.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Thiothixene.
MelperoneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Melperone.
MephentermineThiothixene may decrease the stimulatory activities of Mephentermine.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Thiothixene.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Thiothixene.
MequitazineThiothixene may increase the arrhythmogenic activities of Mequitazine.
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Thiothixene.
MetaxaloneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Metaxalone.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Thiothixene.
MethadoneThiothixene may increase the QTc-prolonging activities of Methadone.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Thiothixene.
MethamphetamineThiothixene may decrease the stimulatory activities of Methamphetamine.
MethapyrileneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Methapyrilene.
MethaqualoneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Methaqualone.
MethocarbamolThe risk or severity of adverse effects can be increased when Thiothixene is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Thiothixene.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Thiothixene.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Thiothixene.
MethsuximideThe risk or severity of adverse effects can be increased when Thiothixene is combined with Methsuximide.
MethylphenidateThe risk or severity of adverse effects can be increased when Thiothixene is combined with Methylphenidate.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Thiothixene.
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Thiothixene.
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Thiothixene.
MetyrosineThiothixene may increase the sedative activities of Metyrosine.
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Thiothixene.
MexiletineThe metabolism of Thiothixene can be decreased when combined with Mexiletine.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Thiothixene.
MifepristoneMifepristone may increase the QTc-prolonging activities of Thiothixene.
MilnacipranThe risk or severity of adverse effects can be increased when Thiothixene is combined with Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Thiothixene.
MirtazapineThiothixene may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Thiothixene.
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Thiothixene.
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Thiothixene.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Thiothixene.
MoxifloxacinThiothixene may increase the QTc-prolonging activities of Moxifloxacin.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Thiothixene.
NabiloneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Nabilone.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Thiothixene.
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Thiothixene.
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Thiothixene.
NevirapineThe metabolism of Thiothixene can be decreased when combined with Nevirapine.
NilotinibThiothixene may increase the QTc-prolonging activities of Nilotinib.
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Thiothixene.
Nitrous oxideThe risk or severity of adverse effects can be increased when Thiothixene is combined with Nitrous oxide.
NormethadoneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Normethadone.
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Thiothixene.
OfloxacinThiothixene may increase the QTc-prolonging activities of Ofloxacin.
OlanzapineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Olanzapine.
OlopatadineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Olopatadine.
OndansetronThiothixene may increase the QTc-prolonging activities of Ondansetron.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Thiothixene.
OpiumThe risk or severity of adverse effects can be increased when Thiothixene is combined with Opium.
OrphenadrineThiothixene may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Thiothixene.
OsanetantThe risk or severity of adverse effects can be increased when Thiothixene is combined with Osanetant.
OsimertinibThe serum concentration of Thiothixene can be decreased when it is combined with Osimertinib.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Thiothixene.
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Thiothixene.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Thiothixene.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Thiothixene.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Thiothixene.
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Thiothixene.
PanobinostatThiothixene may increase the QTc-prolonging activities of Panobinostat.
ParaldehydeThiothixene may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Thiothixene.
ParoxetineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Paroxetine.
PazopanibThiothixene may increase the QTc-prolonging activities of Pazopanib.
Peginterferon alfa-2bThe serum concentration of Thiothixene can be increased when it is combined with Peginterferon alfa-2b.
PentamidineThiothixene may increase the QTc-prolonging activities of Pentamidine.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Thiothixene.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Thiothixene.
PerampanelThe risk or severity of adverse effects can be increased when Thiothixene is combined with Perampanel.
PerflutrenThiothixene may increase the QTc-prolonging activities of Perflutren.
PerospironeThe risk or severity of adverse effects can be increased when Thiothixene is combined with Perospirone.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Thiothixene.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Thiothixene.
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Thiothixene.
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Thiothixene.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Thiothixene is combined with Phenoxyethanol.
PhentermineThiothixene may decrease the stimulatory activities of Phentermine.
PhenytoinThe risk or severity of adverse effects can be increased when Thiothixene is combined with Phenytoin.
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Thiothixene.
PipamperoneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Pipamperone.
PipotiazineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Pipotiazine.
PizotifenThe risk or severity of adverse effects can be increased when Thiothixene is combined with Pizotifen.
PomalidomideThe risk or severity of adverse effects can be increased when Thiothixene is combined with Pomalidomide.
PramipexoleThiothixene may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Pramocaine.
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Thiothixene.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Thiothixene.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Thiothixene.
PrimaquineThiothixene may increase the QTc-prolonging activities of Primaquine.
PrimidoneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Primidone.
ProcainamideThiothixene may increase the QTc-prolonging activities of Procainamide.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Thiothixene.
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Thiothixene.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Thiothixene.
PromazineThiothixene may increase the QTc-prolonging activities of Promazine.
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Thiothixene.
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Thiothixene.
PropafenoneThiothixene may increase the QTc-prolonging activities of Propafenone.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Thiothixene.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Thiothixene.
PropoxycaineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Propoxycaine.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Thiothixene.
PSD502The risk or severity of adverse effects can be increased when Thiothixene is combined with PSD502.
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Thiothixene.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Thiothixene.
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Thiothixene.
QuinidineThiothixene may increase the QTc-prolonging activities of Quinidine.
QuinineThiothixene may increase the QTc-prolonging activities of Quinine.
RamelteonThe risk or severity of adverse effects can be increased when Thiothixene is combined with Ramelteon.
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Thiothixene.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Thiothixene.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Thiothixene.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Thiothixene.
RifampicinThe metabolism of Thiothixene can be increased when combined with Rifampicin.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Thiothixene.
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Thiothixene.
RomifidineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Romifidine.
RopiniroleThiothixene may increase the sedative activities of Ropinirole.
RopiniroleThe metabolism of Thiothixene can be decreased when combined with Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Thiothixene.
RotigotineThiothixene may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Thiothixene.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Thiothixene is combined with S-Ethylisothiourea.
SaquinavirThiothixene may increase the QTc-prolonging activities of Saquinavir.
ScopolamineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Thiothixene.
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Thiothixene.
SertindoleThe risk or severity of adverse effects can be increased when Thiothixene is combined with Sertindole.
SertralineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Thiothixene.
SimeprevirThe metabolism of Thiothixene can be decreased when combined with Simeprevir.
Sodium oxybateThe risk or severity of adverse effects can be increased when Thiothixene is combined with Sodium oxybate.
SotalolThiothixene may increase the QTc-prolonging activities of Sotalol.
StiripentolThe risk or severity of adverse effects can be increased when Thiothixene is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Thiothixene.
SulfisoxazoleThiothixene may increase the QTc-prolonging activities of Sulfisoxazole.
SulpirideThe risk or severity of adverse effects can be increased when Thiothixene is combined with Sulpiride.
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Thiothixene.
SuvorexantThe risk or severity of adverse effects can be increased when Thiothixene is combined with Suvorexant.
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Thiothixene.
TasimelteonThe risk or severity of adverse effects can be increased when Thiothixene is combined with Tasimelteon.
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Thiothixene.
TelavancinThiothixene may increase the QTc-prolonging activities of Telavancin.
TelithromycinThiothixene may increase the QTc-prolonging activities of Telithromycin.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Thiothixene.
TenofovirThe metabolism of Thiothixene can be decreased when combined with Tenofovir.
TeriflunomideThe serum concentration of Thiothixene can be decreased when it is combined with Teriflunomide.
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Thiothixene.
TetracaineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Thiothixene is combined with Tetrodotoxin.
ThalidomideThiothixene may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Thiothixene.
TheophyllineThe metabolism of Thiothixene can be decreased when combined with Theophylline.
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Thiothixene.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Thiothixene.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Thiothixene.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Thiothixene.
TiagabineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Tiagabine.
TiclopidineThe metabolism of Thiothixene can be decreased when combined with Ticlopidine.
TiletamineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Tiletamine.
TizanidineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Tizanidine.
TolcaponeThe risk or severity of adverse effects can be increased when Thiothixene is combined with Tolcapone.
TopiramateThe risk or severity of adverse effects can be increased when Thiothixene is combined with Topiramate.
ToremifeneThiothixene may increase the QTc-prolonging activities of Toremifene.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Thiothixene.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Thiothixene.
TrazodoneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Trazodone.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Thiothixene.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Thiothixene.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Thiothixene.
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Thiothixene.
TriprolidineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Triprolidine.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Thiothixene.
VandetanibThiothixene may increase the QTc-prolonging activities of Vandetanib.
VemurafenibThe serum concentration of Thiothixene can be increased when it is combined with Vemurafenib.
VemurafenibThiothixene may increase the QTc-prolonging activities of Vemurafenib.
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Thiothixene.
VigabatrinThe risk or severity of adverse effects can be increased when Thiothixene is combined with Vigabatrin.
VilazodoneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Vilazodone.
VortioxetineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Vortioxetine.
XylazineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Xylazine.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Thiothixene.
ZiconotideThe risk or severity of adverse effects can be increased when Thiothixene is combined with Ziconotide.
ZimelidineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Zimelidine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Thiothixene.
ZolazepamThe risk or severity of adverse effects can be increased when Thiothixene is combined with Zolazepam.
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Thiothixene.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Thiothixene.
ZonisamideThe risk or severity of adverse effects can be increased when Thiothixene is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Thiothixene.
ZotepineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Thiothixene is combined with Zuclopenthixol.
Food Interactions
  • Avoid alcohol

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Potassium channel regulator activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name:
DRD2
Uniprot ID:
P14416
Molecular Weight:
50618.91 Da
References
  1. Shultz PJ, Sedor JR, Abboud HE: Dopaminergic stimulation of cAMP accumulation in cultured rat mesangial cells. Am J Physiol. 1987 Aug;253(2 Pt 2):H358-64. [PubMed:3039860 ]
  2. Oades RD, Rao ML, Bender S, Sartory G, Muller BW: Neuropsychological and conditioned blocking performance in patients with schizophrenia: assessment of the contribution of neuroleptic dose, serum levels and dopamine D2-receptor occupancy. Behav Pharmacol. 2000 Jun;11(3-4):317-30. [PubMed:11103886 ]
  3. Seeman P: Atypical antipsychotics: mechanism of action. Can J Psychiatry. 2002 Feb;47(1):27-38. [PubMed:11873706 ]
  4. Wu S, Xing Q, Gao R, Li X, Gu N, Feng G, He L: Response to chlorpromazine treatment may be associated with polymorphisms of the DRD2 gene in Chinese schizophrenic patients. Neurosci Lett. 2005 Mar 7;376(1):1-4. Epub 2004 Dec 2. [PubMed:15694263 ]
  5. Wu SN, Gao R, Xing QH, Li HF, Shen YF, Gu NF, Feng GY, He L: Association of DRD2 polymorphisms and chlorpromazine-induced extrapyramidal syndrome in Chinese schizophrenic patients. Acta Pharmacol Sin. 2006 Aug;27(8):966-70. [PubMed:16867246 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  7. Seeman P: Dopamine D2 receptors as treatment targets in schizophrenia. Clin Schizophr Relat Psychoses. 2010 Apr;4(1):56-73. doi: 10.3371/CSRP.4.1.5. [PubMed:20643630 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name:
DRD1
Uniprot ID:
P21728
Molecular Weight:
49292.765 Da
References
  1. Shultz PJ, Sedor JR, Abboud HE: Dopaminergic stimulation of cAMP accumulation in cultured rat mesangial cells. Am J Physiol. 1987 Aug;253(2 Pt 2):H358-64. [PubMed:3039860 ]
  2. Kanba S, Suzuki E, Nomura S, Nakaki T, Yagi G, Asai M, Richelson E: Affinity of neuroleptics for D1 receptor of human brain striatum. J Psychiatry Neurosci. 1994 Jul;19(4):265-9. [PubMed:7918347 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Virus receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates...
Gene Name:
HTR2A
Uniprot ID:
P28223
Molecular Weight:
52602.58 Da
References
  1. Kusumi I, Takahashi Y, Suzuki K, Kameda K, Koyama T: Differential effects of subchronic treatments with atypical antipsychotic drugs on dopamine D2 and serotonin 5-HT2A receptors in the rat brain. J Neural Transm (Vienna). 2000;107(3):295-302. [PubMed:10821438 ]
  2. Yamada J, Sugimoto Y, Horisaka K: Serotonin2 (5-HT2) receptor agonist 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) inhibits chlorpromazine- and haloperidol-induced hypothermia in mice. Biol Pharm Bull. 1995 Nov;18(11):1580-3. [PubMed:8593484 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Toxic substance binding
Specific Function:
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.
Gene Name:
ALB
Uniprot ID:
P02768
Molecular Weight:
69365.94 Da
References
  1. Kitamura K, Omran AA, Nagata C, Kamijima Y, Tanaka R, Takegami S, Kitade T: Effects of inorganic ions on the binding of triflupromazine and chlorpromazine to bovine serum albumin studied by spectrometric methods. Chem Pharm Bull (Tokyo). 2006 Jul;54(7):972-6. [PubMed:16819214 ]
  2. Rukhadze MD, Bezarashvili GS, Sidamonidze NS, Tsagareli SK: Investigation of binding process of chlorpromazine to bovine serum albumin by means of passive and active experiments. Biomed Chromatogr. 2001 Oct;15(6):365-73. [PubMed:11559920 ]
  3. Silva D, Cortez CM, Louro SR: Quenching of the intrinsic fluorescence of bovine serum albumin by chlorpromazine and hemin. Braz J Med Biol Res. 2004 Jul;37(7):963-8. Epub 2004 Jun 22. [PubMed:15264002 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Secondary active organic cation transmembrane transporter activity
Specific Function:
Translocates a broad array of organic cations with various structures and molecular weights including the model compounds 1-methyl-4-phenylpyridinium (MPP), tetraethylammonium (TEA), N-1-methylnicotinamide (NMN), 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP), the endogenous compounds choline, guanidine, histamine, epinephrine, adrenaline, noradrenaline and dopamine, and the drugs quinine...
Gene Name:
SLC22A1
Uniprot ID:
O15245
Molecular Weight:
61153.345 Da
References
  1. Bednarczyk D, Ekins S, Wikel JH, Wright SH: Influence of molecular structure on substrate binding to the human organic cation transporter, hOCT1. Mol Pharmacol. 2003 Mar;63(3):489-98. [PubMed:12606755 ]
Comments
comments powered by Disqus
Drug created on August 29, 2007 14:17 / Updated on August 17, 2016 12:23